Pilot Study on Intermittent Fasting with Immune Checkpoint Inhibitors Initiated
A pilot study is underway to assess the feasibility and safety of intermittent fasting in patients undergoing ICI therapy.
Phase III
WVU Cancer Institute
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The pilot study on intermittent fasting in conjunction with immune checkpoint inhibitors could significantly influence treatment protocols in oncology. If successful, it may lead to improved patient outcomes and adherence, prompting further research and potential integration into standard clinical practice.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results on adherence, side effects, and biomarker changes, as well as any subsequent studies that may arise from this pilot.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.